



California State Board of Pharmacy
2720 Gateway Oaks Drive, Suite 100
Sacramento, CA 95833
Phone: (916) 518-3100 Fax: (916) 574-8618
www.pharmacy.ca.gov

Business, Consumer Services and Housing Agency
Department of Consumer Affairs
Gavin Newsom, Governor



**California State Board of Pharmacy
Department of Consumer Affairs
Public Board Meeting Minutes**

Date: August 30, 2023

Locations: Board of Pharmacy
2720 Gateway Oaks Drive, Suite 100
1st Floor Hearing Room
Sacramento, CA 95833

California Contractors State Licensing Board
12501 East Imperial Highway, Suite 600, Hearing Room
Norwalk, CA 90650

Fresno Water Resources Building
3374 East Shields Ave, Room 1013
Fresno, CA 93726

Alfred E. Alquist Building, Auditorium
100 Paseo De San Antonio
San Jose, CA 95113

Department of Rehabilitation
150 S. Los Robles Ave., Suite 300
Third Floor Conference Room #312
Pasadena, CA 91101

California Contractors State Licensing Board
9246 Lightwave Ave., Ste 130
San Diego, CA 92123

Board Members

Present: Seung Oh, Licensee Member, President
Jessica Crowley, Licensee Member, Vice President
Renee Barker, Licensee Member
Indira Cameron-Banks, Public Member
Kartikeya "KK" Jha, Licensee Member
Jignesh Patel, Licensee Member
Maria Serpa, Licensee Member
Nicole Thibeau, Licensee Member

Jason Weisz, Public Member

Board Members

Not Present:

Trevor Chandler, Public Member, Treasurer
Jose De La Paz, Public Member

Staff Present:

Anne Sodergren, Executive Officer
Julie Ansel, Assistant Executive Officer
Corinne Gartner, DCA Counsel
Rebecca Bon, DCA Counsel
Trang Song, PharmD, Inspector
Debbie Damoth, Executive Specialist Manager

August 30, 2023

I. Call to Order, Establishment of Quorum, and General Announcements

President Oh called the Board Meeting to order at approximately 9:02 a.m. President Oh reminded all individuals present that the Board is a consumer protection agency charged with administering and enforcing Pharmacy Law. Where protection of the public is inconsistent with other interests sought to be promoted, the protection of the public shall be paramount.

President Oh advised all individuals the meeting was being conducted via WebEx and in person at multiple locations. Dr. Oh advised participants watching the webcast could only observe the meeting. Dr. Oh noted anyone interested in participating in the meeting must join the WebEx meeting using the instructions posted on the Board's website. Department of Consumer Affairs' staff provided general instructions for the WebEx Board Meeting.

Roll call was taken. Board Members present at the Sacramento location: Maria Serpa, Licensee Member; and Jig Patel, Licensee Member. Board Member present at the San Jose location: Renee Barker, Licensee Member. Board Member present at the Fresno location: KK Jha, Licensee Member. Board Members present at the Pasadena location: Indira Cameron-Banks, Public Member; Jessi Crowley, Licensee Member; and Nicole Thibeau, Licensee Member. Board Members present at the San Diego location: Jason Weisz, Public Member; and Seung Oh, Licensee Member. Board staff verified there were no Board Members present at the Norwalk location. A quorum was established.

II. Public Comments on Items Not on the Agenda/Agenda Items for Future Meetings

Members of the public were provided with an opportunity to provide comment for items not on the agenda or agenda items for a future meeting.

No public comment was made by meeting participants in the Sacramento, San Jose, Fresno, Pasadena, San Diego, or Norwalk locations.

Public comment was received via WebEx.

The Board heard comments from pharmacists and representatives of UCSD, Sutter Health, and Cedars Sinai regarding concerns about the proposed compounding regulations including proposed section 1736.1 regarding immediate use compounding; seven specific issues related to proposed sections 1736 and 1737; the impact on shortages of products and of 503Bs on compounding; the significant costs and operational burdens that the proposed compounding regulations would impose on facilities (e.g., segregated compounding areas to require 20 degrees or cooler, changing outer gloves between every single compound, using respirators that were mandated, requiring sterile mats, etc.); the impact of drug shortages and recalls on workforce; and consideration that experts developed USP. The commenters requested additional opportunities for comment and input prior to implementation of the new compounding regulations.

The Board heard comments from pharmacists requesting the Board introduce legislation to allow specialty pharmacy to be included in remote processing as well as to continue the discussion related to remote processing in specialty pharmacies.

The Board heard comments from a representative of CSHP requesting guidance for hospital pharmacies should the pending remote processing bill not be signed by the governor.

Member Crowley left the meeting at 9:21 a.m. and returned at 9:25 a.m.

Members were provided the opportunity to provide comment after public comment was taken and to add items to future agendas. Enforcement and Compounding Committee Chairperson Serpa addressed the compounding regulations comments noting the draft regulations were undergoing the rulemaking process. Dr. Serpa added hearings would be scheduled and encouraged participation and written comments when the draft regulations were published for comment. President Oh noted an agenda item would be scheduled for the September Board Meeting that would address some of the issues raised.

III. Closed Session

Open session concluded at approximately 9:27 a.m. The Board entered closed session at approximately 9:33 a.m. and ended closed session at 10:59 a.m.

IV. Adjournment

The Board resumed open session for the purposes of adjourning at 11:00 a.m. The Board Meeting concluded at approximately 11:01 a.m.